White House: Drug Pricing In Phase Three Of Health Reform Will Be FDA Reform

The White House has indicated that the drug pricing measures to be included in phase three of health reform will deal with streamlining FDA and bringing generic competition to market. The new information from the Trump team prompts questions on whether Reps. Kurt Schrader (D-OR) and Gus Bilirakis (R-FL)'s bill to create a priority review voucher program to incentive first generics could be included in the health reform package. A Bilirakis aide told Inside Health Policy that they were hopeful...